SB27

DRUG2 trials

Sponsors

Samsung Bioepis Co., Ltd.

Conditions

Non-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage IIIANon-small Cell Lung Cancer Stage IV

Phase 1

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Active, not recruitingNCT06268613

Samsung Bioepis Co., Ltd.Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA

Start: 2024-01-16End: 2026-11-30Updated: 2025-11-17

Phase 3

A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer

Active, not recruitingNCT06348199

Samsung Bioepis Co., Ltd.Non-small Cell Lung Cancer Stage IV

Start: 2024-03-12End: 2026-09-30Updated: 2025-11-17